Stabilization and solubilization of difluprednate in aqueous cyclodextrin solution and its characterization for ophthalmic delivery

dc.contributorHáskóli Íslandsen_US
dc.contributorUniversity of Icelanden_US
dc.contributor.authorPrajapati, Manisha
dc.contributor.authorLoftsson, Thorsteinn
dc.contributor.departmentLyfjafræðideild (HÍ)en_US
dc.contributor.departmentFaculty of Pharmaceutical Sciences (UI)en_US
dc.contributor.schoolHeilbrigðisvísindasvið (HÍ)en_US
dc.contributor.schoolSchool of Health Sciences (UI)en_US
dc.date.accessioned2022-03-23T13:54:13Z
dc.date.available2022-03-23T13:54:13Z
dc.date.issued2022-01
dc.descriptionPublisher´s version / Útgefin greinen_US
dc.description.abstractDifluprednate is a synthetic glucocorticoid used for the treatment of postoperative inflammation and pain associated with endogenous uveitis. It is very lipophilic with limited aqueous solubility and stability. The only available marketed formulation is an oil-in-water ophthalmic emulsion that has many drawbacks. Cyclodextrin (CD) molecules are widely used to increase the solubility and stability of hydrophobic drugs through the for- mation of drug/CD complexes. This study aims to investigate degradation kinetics, stability and solubility of difluprednate in aqueous CD solutions in an effort to develop aqueous eye drop vehicle for ophthalmic delivery. Phase-solubility and kinetics studies were performed in presence of different CDs and polymers. Characterization of the drug/CD complexes was done using techniques like NMR, DSC, and FTIR. The results show that diflu- prednate has maximum stability at pH 5 in aqueous CD solution. HPγCD was found to be the best solubilizer and stabilizer among all the CDs tested. The stability was further improved with the combination of HPγCD and different polymers. Characterization of the difluprednate/HPγCD complex in solid and solution state confirmed the presence of a drug/CD complex. It was possible to solubilize 0.1% difluprednate using HPγCD and stabilize the drug using combination of CD and polymer in aqueous solutionen_US
dc.description.sponsorshipThis work was financially supported by the European Union grant no. MSCA-ITN-2017-765441 (transMed) and the Faculty of Pharmaceutical Sciences, University of Iceland.en_US
dc.description.versionPeer-Revieweden_US
dc.format.extent103106en_US
dc.identifier.citationManisha Prajapati, Thorsteinn Loftsson, Stabilization and solubilization of difluprednate in aqueous cyclodextrin solution and its characterization for ophthalmic delivery, Journal of Drug Delivery Science and Technology, Volume 69, 2022, 103106, ISSN 1773-2247,en_US
dc.identifier.doi10.1016/j.jddst.2022.103106
dc.identifier.issn1773-2247
dc.identifier.journalJournal of Drug Delivery Science and Technologyen_US
dc.identifier.urihttps://hdl.handle.net/20.500.11815/2969
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/MSCA-ITN-2017-765441en_US
dc.relation.ispartofseriesJournal of Drug Delivery Science and Technology;69
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSolubilityen_US
dc.subjectStabilityen_US
dc.subjectCyclodextrinsen_US
dc.subjectDifluprednateen_US
dc.subjectLyfjaefnafræðien_US
dc.subjectLyfjameðferðen_US
dc.subjectSkurðsjúklingaren_US
dc.subjectBólguren_US
dc.subject.meshPharmaceutical chemistryen_US
dc.titleStabilization and solubilization of difluprednate in aqueous cyclodextrin solution and its characterization for ophthalmic deliveryen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dcterms.licenseCC BY 4.0 © 2022 The Authors. Published by Elsevieren_US

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Hleð...
Thumbnail Image
Nafn:
1-s2.0-S1773224722000156-main.pdf
Stærð:
4.7 MB
Snið:
Adobe Portable Document Format
Description:
Publisher´s version

Undirflokkur